ALN-ANG3 not checked

Regeneron

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Diabetic Kidney Disease (DKD)
Main trialPhase 2
“This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times”In the company’s words, NCT07271186 on ClinicalTrials.gov

Other drugs for Diabetic Kidney Disease (DKD)

All 12 drugs for Diabetic Kidney Disease (DKD)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 13 Oct 2028 Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Phase 1Active, not recruiting 4 Dec 2026 A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ALN-ANG3

Following is part of Solo: you see every change to ALN-ANG3 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in